Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 24634221
Usatyuk PV, et al. (2014) Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem 289, 13476-91 24634221
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase
HGF PIK3R2 (human) augment treatment-induced increase siRNA inhibits
HGF Met (human) augment treatment-induced increase siRNA inhibits

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase
HGF PIK3R2 (human) augment treatment-induced increase siRNA inhibits
HGF Met (human) augment treatment-induced increase siRNA inhibits

S985-p - Met (human)
Modsite: PHLDRLVsARsVsPt SwissProt Entrez-Gene
Orthologous residues
Met (human): S985‑p, Met iso2 (human): S1003‑p, Met (mouse): S983‑p, Met (rat): S986‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase

Y1003-p - Met (human)
Modsite: VsNEsVDyRAtFPED SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1003‑p, Met iso2 (human): Y1021‑p, Met (mouse): Y1001‑p, Met (rat): Y1004‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase

Y1234-p - Met (human)
Modsite: RDMyDkEyysVHNkt SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1234‑p, Met iso2 (human): Y1252‑p, Met (mouse): Y1232‑p, Met (rat): Y1235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase

Y1235-p - Met (human)
Modsite: DMyDkEyysVHNktG SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1235‑p, Met iso2 (human): Y1253‑p, Met (mouse): Y1233‑p, Met (rat): Y1236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase

Y1313-p - Met (human)
Modsite: EyCPDPLyEVMLkCW SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1313‑p, Met iso2 (human): Y1331‑p, Met (mouse): Y1311‑p, Met (rat): Y1314‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase

Y1349-p - Met (human)
Modsite: stFIGEHyVHVNAty SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1349‑p, Met iso2 (human): Y1367‑p, Met (mouse): Y1347‑p, Met (rat): Y1350‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase

Y464-p - PIK3R2 (human)
Modsite: sREyDQLyEEytRTS SwissProt Entrez-Gene
Orthologous residues
PIK3R2 (human): Y464‑p, PIK3R2 (mouse): Y458‑p, PIK3R2 (rat): Y458‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HLMVECs
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
HGF Met (human) augment treatment-induced increase siRNA inhibits
LY294002 HGF inhibit treatment-induced increase
Su11274 HGF inhibit treatment-induced increase